Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameScience Board to the Food and Drug AdministrationAgency NameDepartment of Health and Human Services
Fiscal Year2018Committee Number81
Original Establishment Date9/25/1992Committee StatusChartered
Actual Termination Date Committee URLhttp://www.fda.gov/AdvisoryCommittees/Committee...
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*21
Current Charter Date6/26/2018Designated Fed Officer Position Title*DFO, Office of the Chief Scientist
Date Of Renewal Charter6/26/2020Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Rakesh
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*Raghuwanshi
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixMPH
Specific Establishment Authority*21 U.S.C. 394Designated Federal Officer Phone*(301) 796-4769
Effective Date Of Authority*11/28/1990Designated Federal Officer Fax*301-847-3536
Committee Type*ContinuingDesignated Federal Officer Email*rakesh.raghuwanshi@fda.hhs.gov
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Science Board makes recommendations to the FDA specifically aimed at enhancing the science and research of the Agency. The Science Board to the Food and Drug Administration (Board) advises the Commissioner in discharging responsibilities as they relate to addressing specific and technically complex scientific issues of regulatory importance to FDA. The Board consists of a group of senior scientists with exceptionally accomplished backgrounds in evolving areas of new scientific research which will provide advice and further interaction between FDA, industry, academia, and other government agencies on technically complicated issues of regulatory importance. The Science Board has also completed an Agency-wide external peer review of scientific and research programs and will use the findings as a basis for future direction and guidance to the Agency.
How is membership balanced?*Members are experts in the fields of food science, safety, and nutrition; chemistry; pharmacology; translational and clinical medicine and research; toxicology; biostatistics; medical devices; imaging; robotics; cell and tissue based products; regenerative medicine; public health and epidemiology; international health and regulation; product safety; product manufacturing sciences and quality; and other scientific areas relevant to FDA regulated products such as systems biology, informatics, nanotechnology, and combination products. Members represent academia and industry and include one technically qualified member identified with consumer interests.
How frequent & relevant are cmte mtgs?*The Science Board met one (1) time in FY18 to discuss issues related to the science programs of the agency. In the FY18 meeting, the Science Board issued a report on the CBER Research Program, heard about FDA's Patient Affairs Initiative,and discussed how the agency can leverage its existing tools and authorities, and work with stakeholders, to better address the complex scientific, public health and technology challenges it faces today
Why advice can't be obtained elsewhere?*Members of the Science Board are drawn from the highest scientific levels of academia, industry, research, and/or clinical practice. Their advice and guidance lend credibility to the agency's science planning and its approach to specific scientific and technical issues.
Why close or partially close meetings?This committee did not hold any closed meeting for FY18.
Recommendation RemarksNo reports required for this committee in FY18.

FDA opted not to fill vacancies on the committee this year.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesYes
Outcome Major Policy ChangesYesAction Issued New RegulationsYes
Outcome Advance In Scientific ResearchYesAction Proposed LegislationYes
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionYesAction CommentThe Agency has reordered research priorities and made appropriate shifts in resources to acheive those priorities in response to Science Board recommendations.
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThe utilization of the Science Board enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the committee resulted in advice for the improvement of public health, for which it is difficult to assign a financial value.Grants Review CommentNA
Number Of Recommendations*137Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe number of recommendations reflects the approximate number of recommendations provided to the agency from FY 2003 thru FY 2018.Access Agency WebsiteYes
% of Recs Fully Implemented*84.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice. This number represents an approximation of the percentage of recommendations that the agency has fully implemented or plans to fully implement.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback CommentWhen appropriate, information is made available to the public.Narrative Description*FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Science Board supports FDA's strategic priorities by (provide a narrative for your committee).
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$3,358.00Est Payments to Non-Fed Members Next FY*$25,702.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$50,095.00Estimated Payments to Federal Staff*$52,119.00
Payments to Consultants* Est. Payments to Consultants Next FY*$3,281.00
Travel Reimb. For Non-Federal Members*$5,382.00Est Travel Reimb Non-Fed Members nextFY*$16,706.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$14,394.00Est. Other Costs Next FY*$16,809.00
Total Costs$73,229.00Est. Total Next FY*$114,617.00
Federal Staff Support (FTE)*0.30Est. Fed Staff Support Next FY*0.30
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

  
ActionCommittee System IDCommittee NameFiscal Year
 COM-001969Science Board to the Food and Drug Administration2017
 COM-002422Science Board to the Food and Drug Administration2016
 COM-004183Science Board to the Food and Drug Administration2015
 COM-004516Science Board to the Food and Drug Administration2014
 COM-005939Science Board to the Food and Drug Administration2013
 COM-006690Science Board to the Food and Drug Administration2012
 COM-007994Science Board to the Food and Drug Administration2011
 COM-008791Science Board to the Food and Drug Administration2010
 COM-010295Science Board to the Food and Drug Administration2009
 COM-010820Science Board to the Food and Drug Administration2008
 COM-012070Science Board to the Food and Drug Administration2007
 COM-012808Science Board to the Food and Drug Administration2006
 COM-013988Science Board to the Food and Drug Administration2005
 COM-014806Science Board to the Food and Drug Administration2004
 COM-015937Science Board to the Food and Drug Administration2003
 COM-016522Science Board to the Food and Drug Administration2002
 COM-017599Science Board to the Food and Drug Administration2001
 COM-018546Science Board to the Food and Drug Administration2000
 COM-019802Science Board to the Food and Drug Administration1999
 COM-020294Science Board to the Food and Drug Administration1998
 COM-021694Science Board to the Food and Drug Administration1997